NeuroBo Pharmaceuticals, Inc. (NRBO)

NASDAQ: NRBO · IEX Real-Time Price · USD
0.497
-0.019 (-3.66%)
At close: Sep 25, 2023, 4:00 PM
0.491
-0.006 (-1.25%)
Pre-market: Sep 26, 2023, 8:03 AM EDT
-3.66%
Market Cap 19.10M
Revenue (ttm) n/a
Net Income (ttm) -11.13M
Shares Out 38.43M
EPS (ttm) 1.44
PE Ratio 0.35
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 171
Open 0.480
Previous Close 0.516
Day's Range 0.477 - 0.515
52-Week Range 0.361 - 17.500
Beta -0.76
Analysts Strong Buy
Price Target 6.00 (+1,107.0%)
Earnings Date Nov 13, 2023

About NRBO

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Hyung-Heon Kim
Employees 2
Stock Exchange NASDAQ
Ticker Symbol NRBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for NRBO stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target
$6.0
(1,107.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Two-Part Design Provides Optionality for Interim Analysis in First Half of 2024 Full Data Readout Expected in the Second Half of 2024 BOSTON , Sept. 15, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, I...

11 days ago - PRNewsWire

NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT

BOSTON , Aug. 14, 2023  /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appoi...

6 weeks ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Dosing of First Patient in Phase 2a Clinical Trial of DA-1241 Expected September 2023 Cash and Cash Equivalents of $28.7 Million, Expected to Fund the Company into 2024, Through Multiple Clinical Mile...

6 weeks ago - PRNewsWire

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

BOSTON , Aug. 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has...

7 weeks ago - PRNewsWire

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

BOSTON , Aug. 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has...

7 weeks ago - PRNewsWire

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models

Preclinical Data Also Show DA-1726 Effectively Reduces Body Weight and Glycemic Control Data Presented in One ePoster Theater Discussion and Two General Poster Presentations at the American Diabetes A...

3 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions

BOSTON , June 13, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that data ...

3 months ago - PRNewsWire

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

BOSTON , May 12, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appoint...

4 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Initiation of Phase 2a Clinical Trial Expected to Occur in Q3 2023 BOSTON , May 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest ...

5 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

BOSTON , April 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today announced that it has s...

6 months ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

Company Pipeline to Focus on Cardiometabolic Disease Cash and Cash Equivalents to Fund the Company into 2024 BOSTON , March 30, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a cli...

6 months ago - PRNewsWire

NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President

Experienced Executive Brings Approximately 40 Years of Pharmaceutical, Clinical Development and Operational Experience BOSTON , Jan. 18, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRB...

8 months ago - PRNewsWire

NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT

CLOSES EXCLUSIVE LICENSE OF ASSETS FROM DONG-A BOSTON , Nov. 8, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company f...

11 months ago - PRNewsWire

NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT

BOSTON , Nov. 4, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) (the "Company" or "NeuroBo") today announced the pricing of an underwritten public offering of units and a concurrent ...

11 months ago - PRNewsWire

NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria

BOSTON , Sept. 29, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. ("NeuroBo") (Nasdaq: NRBO) today announced that on September 27, 2022, NeuroBo received formal notice from the Listing Qualificati...

1 year ago - PRNewsWire

Why NeuroBo Pharmaceuticals Shares Are Up Over 50% - NeuroBo Pharmaceuticals (NASDAQ:NRBO)

NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) shares are trading higher by 56.44%. Strength may be due to short interest in the stock and social media interest.

1 year ago - Benzinga

NeuroBo Pharmaceuticals (NASDAQ:NRBO) – Why Neurobo Pharmaceuticals Shares Are Skyrocketing

Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) shares are trading higher by 53.74% to $25.92 Thursday morning after the company announced Dong-A has licensed its global exclusive development rights of DA-...

1 year ago - Benzinga

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies

Exclusive License Agreement to Develop and Commercialize Phase II Clinical Stage New Chemical Entity DA-1241 for the Treatment of NASH / Type 2 Diabetes and Phase I Ready DA-1726 for the Treatment of ...

1 year ago - PRNewsWire

NeuroBo Pharmaceuticals (NRBO) Stock Soared After A Stock Split

NeuroBo Pharmaceuticals (NRBO) stock soared Tuesday after initiating a 1-for-30 reverse stock split Monday night.

1 year ago - Forbes

NeuroBo Pharmaceuticals (NASDAQ:NRBO) – What In The World Is Going On With Neurobo Pharmaceuticals Shares?

Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) shares are trading higher by 77.04% to $0.49 Monday morning after the company announced a 1-for-30 reverse stock split.

1 year ago - Benzinga

NeuroBo Pharmaceuticals Announces Reverse Stock Split

BOSTON , Sept. 12, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company, announced today a 1-for-30 reverse split of i...

1 year ago - PRNewsWire

NeuroBo Pharmaceuticals, Inc. Expands Management Team with the Appointment of Matthew Bardin, PharmD, BCPS as Senior Vice President Operations

BOSTON , May 6, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment, effective April 30, 2022 of Matthew Bardin, ...

1 year ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results

BOSTON , April 1, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced financial results for the year ended December 31, 2021. Man...

1 year ago - PRNewsWire

NeuroBo Pharmaceuticals, Inc. Expands Scientific Advisory Board with Appointment of Danamarie Belpulsi, M.D.

BOSTON, March 15, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment, effective immediately, of Danamarie Belpul...

1 year ago - PRNewsWire

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

BOSTON, Jan. 28, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Dire...

1 year ago - PRNewsWire